Company Overview

Bliss GVS Pharma Limited (BSE: 506197, NSE: BLISSGVS) has filed its Annual Report for FY 2025-2026 and audited consolidated financial statements, showcasing strong financial performance and strategic developments.

Financial Performance Highlights

Consolidated Results:

  • Revenue from Operations: ₹9,271.13 crore (FY25: ₹8,097.26 crore), representing 14.5% growth
  • Profit Before Tax: ₹1,895.89 crore, up 50.9% year-over-year
  • Profit After Tax: ₹1,347.28 crore, increasing 53% from previous year
  • Basic EPS: ₹12.23 (FY25: ₹8.02)
  • Diluted EPS: ₹12.00 (FY25: ₹7.95)

Standalone Performance:

  • Total Revenue: ₹7,735.26 lakh with 9% growth
  • Revenue from Operations: ₹7,298.08 lakh
  • Profit Before Tax: ₹1,334.65 lakh
  • Profit After Tax: ₹968.74 lakh
  • EBITDA: ₹1,340.35 lakh with margins of 18%

Capital Structure & Dividend

  • Paid-up Equity Share Capital: ₹105.79 crore (10,57,88,972 equity shares)
  • Final Dividend Recommended: 100% (₹1.00 per equity share), doubling from previous year
  • Interim Dividend Paid: 50% (₹0.50 per share) during FY26
  • Total Dividend Payout: Approximately ₹105.64 crore
  • Record Date for Final Dividend: July 8, 2026
  • Payment Date: On or before August 14, 2026

Debt Reduction & Balance Sheet Strength

  • Prepaid all long-term borrowings, reducing total debt by 96% to ₹29.26 crore
  • Significant reduction in working capital loans
  • Cash and Cash Equivalents: ₹351.42 crore
  • Total Assets: ₹14,924.13 crore
  • Total Equity: ₹12,317.59 crore

Operational Highlights & Expansion

  • Manufacturing: 6 cutting-edge units with US FDA, TGA Australia, EU-GMP, WHO-GMP approvals
  • Geographic Presence: Operations in 60+ countries with 92.8% revenue from international markets
  • Capacity Expansion: Commissioned semi-solid manufacturing facility at Vevoor, Palghar
  • New Subsidiaries: Established Theralife Pharma Ltd (Kenya) and Theralife Pharma RDC Private Limited (DRC)
  • Stake Sale: Divested 51% stake in Nigerian subsidiary Greenlife Bliss Healthcare Ltd for USD 1.3 million

Corporate Governance & Leadership

  • 41st AGM Scheduled: July 15, 2026 through Video Conferencing
  • Board Composition: 6 Directors (1 Executive, 5 Non-Executive Independent)
  • Recommended reappointment of Mr. Narsimha Shibroor Kamath as Managing Director & CEO
  • ESOP Grants: 20,21,000 options granted during year under ESOP 2019 plan

Regulatory Compliance & Audits

  • Filed pursuant to Regulation 34(1) of SEBI Listing Regulations
  • Statutory Auditors: Kalyaniwalla & Mistry LLP issued unmodified opinion
  • Key Audit Matters: Revenue recognition, business development expenses, and IT controls
  • Compliance with Companies Act, 2013 and all SEBI regulations

Key Metrics & Investments

  • R&D Investment: ₹189 million
  • CSR Spending: ₹27 million
  • Solar Power: 9.6 MW installed capacity generating 13 million units
  • Digital Transformation: Implementation of SAP S/4HANA and SAP SuccessFactors
  • Employee Strength: 1,033 permanent employees

Subsequent Events & Outlook

  • No material adjusting events after reporting period
  • Financial statements approved by Board on May 12, 2026
  • Continued focus on international expansion and manufacturing capabilities enhancement
  • Strong balance sheet position supporting future growth initiatives